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Abstract
Health-related quality of life in people with intellectual disabilities can be affected by challenging 
behaviours and side-effects of antipsychotics. The aim of this study was to evaluate the effect 
of discontinuation antipsychotic drugs on health-related quality of life, including data from 
two discontinuation trials: an open-label trial of various antipsychotic drugs and a double-blind 
trial of risperidone. In both studies antipsychotics were discontinued in 14 weeks, with steps of 
12.5% of the baseline dosage every two weeks. Health-related quality of life was measured at 
baseline and at 16 weeks and 40 weeks after baseline, by means of the RAND-36 (domains on 
physical well-being, role limitations caused by physical or emotional problems, vitality, pain, 
mental well-being, social functioning, general health and changes in health). Participants who 
had completely discontinued antipsychotics according to the scheduled discontinuation and 
were still free of use at 40 weeks were compared with those who had incompletely discontinued.
Physical well-being showed an increase in the group that had achieved complete discontinuation. 
Social functioning showed a decrease in the group that incompletely discontinued, which 
recovered at follow-up. Mental well-being decreased at 16 weeks, but recovered at follow-
up, regardless of complete or incomplete discontinuation. To conclude, discontinuation of 
antipsychotics had a positive effect on physical well-being when complete discontinuation was 
possible. When complete discontinuation was not possible, there was a negative effect on health-
related quality of life domains. However, none of the unfavourable effects were irreversible.
Introduction
Antipsychotic drugs are frequently prescribed in people with intellectual disabilities for the 
management of challenging behaviours (O’dwyer et al., 2017); the prevalence rate of antipsychotic 
drug use in the Netherlands is 29.6% (de Kuijper et al., 2010; de Kuijper & Hoekstra, 2017). Contrary 
to what antipsychotic drugs were developed for, i.e. the treatment of psychotic symptoms and 
schizophrenia, the drugs are more often prescribed outside of this licensed indication (off-label) 
in people with intellectual disabilities. Of the prescriptions in the Netherlands, 95% was off-
label, mainly for challenging behaviours (de Kuijper & Hoekstra, 2017; Ramerman, de Kuijper, & 
Hoekstra, 2017). Despite conflicting evidence for their effectiveness in this indication, treatment 
is often long-term (Ahmed et al., 2000; de Kuijper, Evenhuis, Minderaa, & Hoekstra, 2014; Gagiano, 
Read, Thorpe, Eerdekens, & Van Hove, 2005; Tyrer et al., 2008; Zarcone et al., 2001). Moreover, there 
is a risk of side-effects of antipsychotic drugs, for example metabolic symptoms, neurological 
symptoms, and endocrine symptoms (Matson & Mahan, 2010), with 53% of those on long-term 
antipsychotics having one or more extrapyramidal symptoms, 46% overweight or obesity, and 
64% clinically elevated prolactin levels in our previous study (de Kuijper et al., 2013).
Challenging behaviours and the side-effects of antipsychotic drug use can affect health-
related quality of life (Allison, Mackell, & McDonnell, 2003; Faulkner, Cohn, Remington, & Irving, 
2007; Koch et al., 2015; Ramerman, Hoekstra, & de Kuijper, 2018; Scheifes et al., 2016). Health-
related quality of life describes the health status of a person comprehensively. Both physical 
and emotional well-being are considered, as well as the role limitations caused by physical or 
emotional problems (i.e., the ability to participate and perform normal daily tasks and activities), 
social functioning (the ability to participate in normal social activities), pain, and general health 
(Hays & Morales, 2001; Wilson & Cleary, 1995). We previously showed that parkinsonism and 
autonomic symptoms decreased the physical well-being component of quality of life and also 
that challenging behaviours, such as lethargy and irritability influenced quality of life negatively 
despite the use of antipsychotic drugs (Ramerman et al., 2018).
Discontinuation studies have shown that discontinuation of long-term used antipsychotics 
may improve behavioural functioning (Ahmed et al., 2000; de Kuijper et al., 2014; de Kuijper & 
Hoekstra, 2018). We previously showed that this is especially feasible in clients on lower doses 
of antipsychotics and with less severe challenging behaviour (de Kuijper & Hoekstra, 2018). 
As health-related quality of life is related to physical impairments as well as to maladaptive 
behaviour, it may be a useful outcome to use during the discontinuation of off-label prescribed 
antipsychotics (Ramerman et al., 2018). In the present study, we therefore investigated the effects 
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of discontinuation of long-term used antipsychotics for challenging behaviours on health-
related quality of life. We made a comparison between participants who were and were not 
able to withdraw completely from antipsychotic medication. Furthermore, changes in health-
related quality of life were analysed in relation to changes in physical symptoms associated with 
antipsychotic medication and in relation to changes in challenging behaviours.
Methods
Approval from the medical ethical committee of the University Medical Center Groningen was 
obtained for both studies (open-label: 2014/402; double-blind: 2015/171). Informed consent was 
provided by legal representatives or participants themselves when they were competent.
Study design and procedures
In this study data from two different discontinuation trials (de Kuijper & Hoekstra, 2018; 
Ramerman, de Kuijper, & Hoekstra, Submitted) were combined, an open-label discontinuation 
trial (registered in The Netherlands National Trial Register: NTR5519) and a double-blind placebo-
controlled discontinuation trial (registered in The Netherlands National Trial Register (NTR5509)). 
For the current study all data at baseline, 16 weeks (two weeks after scheduled discontinuation), 
and 40 weeks (follow-up, i.e., 40 weeks after baseline) were used from the open-label trial and 
from the discontinuation group of the double-blind trial. The control group from the double-
blind trial was excluded from the analysis.
In total, nine organizations (two mental health care organizations and seven service providers 
of intellectual disability care, including medical and psychological services) participated in the 
studies. Two of the seven service providers participated in both studies. These two organizations 
included their clients using risperidone into the double-blind study and the other antipsychotic 
drug users into the open-label study. In both studies, participants received a proposal for 
discontinuation from their physician.
Participants
Participants were eligible for both studies, when they had an intellectual disability (IQ<70; 
according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) or 
when mentioned in patient’s records), were six years of age or older, used antipsychotic drugs for 
at least one year, had not attempted discontinuation in the last six months and had no diagnosis 
of psychosis, schizophrenia or bipolar disorder according to DSM-IV. Due to practical reasons, 
participants from the double-blind trial were asked to taper their dosage to a maximum of 5 mg 
before the start of the trial, when needed. Participants were allowed to use other psychotropic 
drugs and could receive additional psychological or psychosocial interventions.
Intervention
In both trials discontinuation was scheduled as a 12.5% reduction every two weeks of the 
baseline antipsychotic drug dose. In the double-blind trial, participants were prescribed the 
fluid form of risperidone (1mg/ml) to enable stepwise, placebo-controlled discontinuation. Every 
participant received two bottles of medication. In the discontinuation group, the first bottle 
contained risperidone and the second bottle placebo. During the 14-week withdrawal phase, 
the amount taken from the first bottle lowered with 12.5%, while the amount taken from the 
placebo increased with 12.5% every two weeks.
In both trials, participants were allowed to stop the withdrawal of antipsychotic drugs at any 
time, to taper off more slowly, or restart antipsychotic drugs after complete discontinuation. The 
decision to stop the scheduled discontinuation or the restart of the antipsychotic drugs was the 
responsibility of the participant’s physician. Reasons to stop the scheduled discontinuation could 
be an increase in challenging behaviours, the emergence of psychotic symptoms, or withdrawal 
symptoms.
Outcomes
Outcomes were collected at baseline, 16 weeks (2 weeks after scheduled discontinuation) and 
40 weeks (follow-up) for all participants. Data collection also continued for participants of the 
open-label study when the physician stopped further discontinuation or slowed down the 
tapering off and in the double-blind study when the physician stopped discontinuation and 
the participant was deblinded.
The primary outcome was health-related quality of life as assessed by the 36-item Research and 
Development survey (RAND-36). The RAND-36 is a health-related quality of life questionnaire, 
with domains on physical well-being, role limitations caused by physical or emotional problems, 
social role limitations, mental well-being, vitality, pain, general health and changes in health 
status. The domain of physical well-being includes items on physical activity (such as walking 
stairs or lifting). Furthermore, emotional/mental well-being includes items on happiness, anxiety 
and being down-hearted. Role limitations caused by physical or emotional problems includes 
items on how limitations in physical or emotional well-being impact daily activities, such as work 
or ambitions. The Social functioning domain assessed the impact of physical and mental well-
being on social activities and participation, the Pain domain the amount of pain experienced 
and the level of influence pain had on normal daily functioning, the Vitality domain included 
assessed energy and tiredness, and the domains of general health and health changes assessed 
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a current estimation of health status, the changes that had occurred recently, and expectations 
of future health.
All domains were scored on a scale of 0-100%, with 100% being the highest quality of life on 
that particular domain. The RAND-36 was completed by a proxy (direct support staff or parent/
caretaker) or by a proxy along with the participant by completing a hard copy questionnaire or 
by completing the questionnaire online.
Achievement of complete discontinuation was defined as being discontinued at 16 weeks (2 
weeks after scheduled discontinuation) and remaining off antipsychotic drugs at follow-up (40 
weeks after the start of discontinuation).
Secondary outcomes included challenging behaviours and physical side-effects that were 
associated with health-related quality of life domains, according to our previous study, 
i.e., symptoms of parkinsonism, autonomic symptoms, irritability, lethargy and stereotypy 
(Ramerman et al., 2018). Challenging behaviours were measured with the subscales irritability, 
lethargy, and stereotypy of the Aberrant Behavior Checklist (ABC). Parkinsonism was assessed 
with the Unified Parkinson’s Disease Rating Scale (UPDRS; items 20, 21, 22, 31); and autonomic 
symptoms with the Scale for Outcomes in Parkinson’s disease Autonomic symptoms (SCOPA-
AUT).
Statistical analysis
Baseline differences regarding the participants’ characteristics age, sex, severity of intellectual 
disability, total antipsychotic drug dose converted into Defined Daily Dose (DDD), and use of 
other psychotropic drugs were analysed by Independent t-test for continuous variables and 
Chi-square test for categorical variables. Differences at baseline, at the time point of 16 weeks (2 
weeks after the scheduled discontinuation, and at 40 weeks (follow-up), between the complete 
discontinuation group and the incomplete discontinuation group were assessed with a mixed 
model for repeated measures. The continuous domains of the RAND-36 were the dependent 
variables in the analysis, with group (complete or incomplete discontinuation)*time (baseline, 
16 weeks and 40 weeks), group, and time as fixed effect. Analyses were done according to an 
intention-to-treat principle. An unstructured covariance matrix was used.
The domains of the RAND-36 with significant time*group, time or group effects were included 
in a mixed model for repeated measures analysis, with the irritability, lethargy, and stereotypy 
subscales of the ABC, and the total scores on the UPDRS and SCOPA-AUT as covariates (fixed 
effects). If these covariates had a univariate association with the domains of the RAND-36 
(P<0.05), they were added as covariates in a multivariate model. Analyses were done according 
to an intention-to-treat principle. An unstructured covariance matrix was used. The significance 
threshold for all analyses was p< 0.05. All analyses were performed with the IBM Statistical 
Package for the Social Sciences, 23th edition.
Results
Table 1. presents the baseline characteristics of participants. In total 128 participants started 
discontinuation from antipsychotic drugs. A total of 42% achieved complete discontinuation 
at both 16 and 40 weeks. There were significant differences in sex and severity of intellectual 
disability between participants who achieved complete discontinuation at the time point of 16 
weeks (2 weeks after scheduled discontinuation) and remained off-medication until 40 weeks, 
and those who had not.
Table 1. Baseline characteristics of participants
Participant characteristics Complete 
discontinuation 




at 16 and/or 40 
weeks (n=74)
Test value
Age in years (mean (SD a))b 47.6 (17.8) 47.7 (14.7) te=0.030 (p=0.976)
Sex (%) χ2f=9.37 (p=0.01)
Male 62.6 77
Female 37.4 23





DDDc (mean (SD)) 0.54 (0.48) 0.62 (0.45) t=1.686 (p=0.093)
Use of other psychotropic drugs (%) 32.4 43.9 χ2=5.96 (p=0.051)
Living situationd (%) χ2=3.513 (p=0.319)
Congregated centre 54.7 59.2
Community centre 26.4 21.0
Community living facility 13.2 7.9
Missing 5.7 11.8
Living situation. group size (%) χ2=5.325 (p=0.256)
1-4 persons 15.1 21.1
5-8 persons 45.3 43.4
9-12 persons 24.5 14.5
Independent 5.7 3.9
Missing 9.4 17.1
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Table 1. Continued
Participant characteristics Complete 
discontinuation 


















b Both adults and children were included. 7.5% was aged under 18 years.
c DDD= Defined Daily Dosage: Average maintenance dosage calculated by dividing the actual dosage by the 
DDD defined by The World Health Organization.
d Congregated centres are large campus facilities, community centres are larger living facilities (>50 residents) 
in the community; community living facilities are group homes in the community (<20 residents).
e t is the test value gained from the independent t-test, with p as the significance level.
f χ2 is the test value gained from the Chi-square test, with p as the significance level.
Table 2 and Figure 1 show the scores on the domains of the RAND-36 at baseline, 16 weeks and 
40 weeks. A significant time*group effect was found for physical well-being, indicating a steeper 
increase in well-being scores for the complete discontinuation group. Both social functioning and 
role limitations caused by physical problems had a significant time*group interaction, showing 
a deterioration at the time point of scheduled discontinuation, followed by an improvement at 
follow-up in the incomplete discontinuation group, while the complete discontinuation group 
remained stable. In addition, general health also had a significant time*group interaction, 
showing a steeper increase in the complete discontinuation group during discontinuation, that 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1 presents the overall development of the quality of life domains over time, for the 
complete and incomplete discontinuation group. The domain for emotional well-being had 
a significant time effect (F=9.516; p<0.001) and a significant group effect (F=4.749; p=0.031). 
Emotional well-being was lower at all time points for the incomplete discontinuation group. 
Furthermore, emotional well-being scores deteriorated in both groups at the time point of 16 
weeks, followed by an improvement in both groups at 40 weeks.
Table 3. The association between the change in domains of the RAND-36a during discontinuation of 
antipsychotic drugs with the change in severity of challenging behaviour symptoms and change severity 











Parkinsonism (UPDRSb) -2.77 (0.70) 15.594 (p<0.001)
Autonomic symptoms 
(SCOPA-AUTc)





Parkinsonism (UPDRS) -2.31 (0.75) 9.521 (p<0.001)
Autonomic symptoms 
(SCOPA-AUT)
-0.53 (0.15) 12.516 (p<0.001)
Social functioning Irritability (ABCd) -0.95 (0.21) 19.859 (p<0.001)
Lethargy (ABC) -0.80 (0.26) 9.411 (p=0.003)
Stereotypy (ABC) 0.32 (0.37) 0.744 (p=0.392)
Mental/emotional 
well-being
Irritability (ABC) -0.66 (0.13) 24.411 (p<0.001)
Lethargy (ABC) -0.32 (0.14) 5.111 (p=0.028)
Stereotypy (ABC) -0.05 (0.24) 0.038 (p=0.847)
General Health Parkinsonism (UPDRS) -1.64 (0.61) 7.357 (p=0.011)
Autonomic symptoms 
(SCOPA-AUT)
-0.38 (0.12) 10.262 (p=0.002)
Lethargy (ABC) -0.51 (0.14) 12.466 (p<0.001)
a RAND-36=36-item Research and Development survey.
b UPDRS= Unified Parkinson’s Disease Rating Scale.
c SCOPA-AUT= Scales for Outcomes in Parkinson’s disease- Autonomic symptoms.
d ABC= Aberrant Behavior Checklist.
e F is the test value gained from the mixed methods analysis, with p as the significance level.
Table 3. shows the association between the change that occurs in the domains of the RAND-36 
during discontinuation with the change that occurred in severity of side-effects and with the 
change in severity of challenging behaviours. There was a negative main effect of the UPDRS 
and SCOPA-AUT scores on physical well-being. Moreover, changes in irritability and lethargy 
were negatively associated with changes in both mental well-being and social functioning. 
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Last, general health was negatively associated with scores on the UPDRS, SCOPA-AUT, and the 
lethargy subscale of the ABC.
Discussion
The aim of the study was to investigate the effects of discontinuation of long-term used 
antipsychotics prescribed for the management of challenging behaviours, on health-
related quality of life. Physical well-being improved in participants who achieved complete 
discontinuation. This increase in physical well-being may be related to the attenuation of 
side-effects, e.g. of parkinsonism. This beneficial effect of discontinuation adds to the findings 
of previous studies that showed favourable effects of discontinuation on weight, body mass 
index, waist circumference, and prolactin and testosterone levels (de Kuijper, Mulder, Evenhuis, 
Visser, & Hoekstra, 2013; de Kuijper, Mulder, Evenhuis, Visser, & Hoekstra, 2014; Ramerman et al., 
Submitted).
Full or attempted discontinuation led to a decline in mental well-being which subsequently 
recovered. The initial worsening may be a direct consequence of withdrawing the therapeutic 
effect of the antipsychotic medication. It is reassuring and of clinical relevance that the worsening 
was only temporal, also when participants remained off-medication. Mental well-being was 
lower at all time points in the group of participants with incomplete discontinuation, compared 
to the participants with complete discontinuation. This probably indicates that those who were 
not able to discontinue their antipsychotics had more severe challenging behaviours, including 
irritability and lethargy.
The changes in mental well-being were negatively related to changes in symptoms of irritability 
and lethargy, indicating an increase in mental well-being when there is a decrease in challenging 
behaviours. The association of challenging behaviours, such as irritability and lethargy with 
mental well-being is in line with previous studies (Koch et al., 2015; Ramerman et al., 2018). 
In addition, during a previous discontinuation study, we found an increase in the severity of 
individually chosen target behaviours as measured with a Visual Analogue scale at the time point 
of scheduled discontinuation in those with incomplete discontinuation of the antipsychotic drugs 
and no change in those with complete discontinuation (de Kuijper et al., 2014). Furthermore, 
McNamara (2017) found an increase in aggression and irritability in those who discontinued 
risperidone (McNamara et al., 2017).
The effects of discontinuation on social functioning were similar to those on role limitations 
caused by physical or mental problems. Overall, the results indicate that participants with 
incomplete discontinuation initially showed worse functioning, at the time point of scheduled 
discontinuation, which improved again at follow-up, after discontinuation had been suspended. 
The results indicate that an increase in irritability and lethargy during discontinuation will 
decrease social functioning. Furthermore, the results also indicate that when symptoms of 
parkinsonism or autonomic symptoms decrease during discontinuation, experienced role 
limitations will improve.
This study is the first to study the effects of discontinuation of antipsychotic drugs on health-
related quality of life, in people with intellectual disability. However, there are also some 
limitations. First, we used the RAND-36 as a measure of health-related quality of life, a scale 
widely used and validated, but not for the use in people with intellectual disabilities or for 
completion by proxies. Validation of this scale for people with intellectual disabilities (and their 
proxies) may support future research on this subject. Second, we combined two studies with 
a different design. Although the schedule of discontinuation was the same, there might be a 
difference in results between blind discontinuation and open discontinuation. It can be expected 
that participants in the double-blind study are more inclined to continue with discontinuation, 
even when discontinuation becomes more difficult, by for example an increase in challenging 
behaviour. Moreover, there may be a difference in bias between the two trials on the completion 
of the RAND-36 and other scales, by the caregivers. In the open-trial, the caregivers were not 
blinded and all participants were discontinuing antipsychotic drugs. In contrast, in the double-
blind trial, caregivers were blinded on the discontinuation of their client when completing the 
questionnaires at baseline and week 16. This may have affected the answers provided on the 
scales. Last, there was no control group to compare the normal fluctuation in health-related 
quality of life with.
Clinical implications
The results of this study have implications for clinical practice. There is evidence that successful 
complete discontinuation of antipsychotic drugs has beneficiary effects on physical well-being. 
Even if unsuccessful discontinuation may negatively affect the mental functioning of the client, 
this will only be temporary.
Conclusion
To conclude, health-related quality of life is both positively and negatively influenced by the 
discontinuation of antipsychotic drugs. The changes in domains of health-related quality 
of life are negatively associated with changes in challenging behaviours and symptoms of 
parkinsonism. Physical well-being improves when complete discontinuation is possible. Mental 
well-being can be expected to show a temporary decrease, independent of the achievement 
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of complete discontinuation. Furthermore, in those with incomplete discontinuation social 
functioning is clearly affected however this is also temporarily. These results suggest that 
attempting discontinuation will not permanently affect the domains of health-related quality 
of life. Moreover, when complete discontinuation of antipsychotic drugs is possible, an increase 
in physical well-being may be expected.
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